1. Home
  2. IBRX vs THG Comparison

IBRX vs THG Comparison

Compare IBRX & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$8.28

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Logo Hanover Insurance Group Inc

THG

Hanover Insurance Group Inc

N/A

Current Price

$173.37

Market Cap

6.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
IBRX
THG
Founded
2014
1852
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.3B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
IBRX
THG
Price
$8.28
$173.37
Analyst Decision
Strong Buy
Buy
Analyst Count
6
6
Target Price
$12.50
$198.00
AVG Volume (30 Days)
31.9M
201.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
2.18%
EPS Growth
38.71
55.21
EPS
N/A
18.16
Revenue
$113,288,000.00
$6,594,400,000.00
Revenue This Year
$88.57
$3.04
Revenue Next Year
$146.98
$4.24
P/E Ratio
N/A
$9.61
Revenue Growth
668.31
5.72
52 Week Low
$1.83
$147.76
52 Week High
$12.43
$188.18

Technical Indicators

Market Signals
Indicator
IBRX
THG
Relative Strength Index (RSI) 52.60 43.47
Support Level $2.27 $166.97
Resistance Level $12.43 $180.14
Average True Range (ATR) 1.07 3.42
MACD -0.31 -0.40
Stochastic Oscillator 11.91 16.10

Price Performance

Historical Comparison
IBRX
THG

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

Share on Social Networks: